J. Lambert

发表

Cytotoxicity of gelonin conjugated to targeting molecules: effects of weak amines, monensin, adenovirus, and adenoviral capsid proteins penton, hexon, and fiber.

W. Blättler, V. Goldmacher, J. Lambert, 1989, Molecular pharmacology.

The galactose-binding sites of the cytotoxic lectin ricin can be chemically blocked in high yield with reactive ligands prepared by chemical modification of glycopeptides containing triantennary N-linked oligosaccharides.

W. Blättler, V. Goldmacher, J. Lambert, 1991, Biochemistry.

Clinical trials with blocked ricin immunotoxins.

D. Esseltine, T. Lynch, J. Lambert, 1998, Current topics in microbiology and immunology.

A Phase I Study of Cantuzumab Mertansine Administered as a Single Intravenous Infusion Once Weekly in Patients with Advanced Solid Tumors

R. Schilsky, M. Ratain, M. Russo, 2004, Clinical Cancer Research.

Humanization of murine monoclonal antibodies through variable domain resurfacing.

A R Rees, J T Pedersen, A. Henry, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.

John M Lambert, Wai Lee T Wong, Guangmin Li, 2008, Cancer research.

Drug-conjugated monoclonal antibodies for the treatment of cancer.

J. Lambert, 2005, Current opinion in pharmacology.

Cross-links between ribosomal proteins of 30S subunits in 70S tight couples and in 30S subunits.

R. Traut, J. Lambert, J. Cover, 1983, Biochemistry.

Preparation and characterization of interleukin-2-gelonin conjugates made using different cross-linking reagents.

J. Ritz, W. Blättler, J. Lambert, 1994, Bioconjugate chemistry.

Purification and biochemical characterization of immunotoxins.

W. Blättler, J. Lambert, W. Blattler, 1988, Cancer treatment and research.

The site of action of six different ribosome-inactivating proteins from plants on eukaryotic ribosomes: the RNA N-glycosidase activity of the proteins.

K. Tsurugi, Y. Endo, J. Lambert, 1988, Biochemical and biophysical research communications.

New developments for antibody-drug conjugate-based therapeutic approaches.

J. Lambert, B. D. de Goeij, 2016, Current opinion in immunology.

Eradication of large colon tumor xenografts by targeted delivery of maytansinoids.

N. Kedersha, R. Chari, W. Blättler, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Antibody-maytansinoid conjugates: A new strategy for the treatment of cancer

J. Lambert, 2010, Drugs of the Future.

A Case Study Comparing Heterogeneous Lysine- and Site-Specific Cysteine-Conjugated Maytansinoid Antibody-Drug Conjugates (ADCs) Illustrates Benefits of Lysine Conjugation.

E. K. Maloney, T. Keating, M. McShea, 2019, Molecular pharmaceutics.

An immunotoxin composed of a monoclonal antitransferrin receptor antibody linked by a disulfide bond to the ribosome-inactivating protein gelonin: potent in vitro and in vivo effects against human tumors.

J. Jackson, V. Goldmacher, J. Lambert, 1987, Journal of the National Cancer Institute.

The anatomy of a multifunctional enzyme.

J. Coggins, D. Mousdale, I. Anton, 1987, Biochemical Society transactions.

Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.

E. K. Maloney, J. Pinkas, Y. Setiady, 2017, Bioconjugate chemistry.

Anti-CD 38-Blocked Ricin : An Immunotoxin for the Treatment of Multiple Myeloma

K. Anderson, J. Lambert, R. Rasmussen, 2002 .

Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors.

R. Arceci, B. Guild, R. O'Connor, 1995, Blood.

Immunotoxins and Antibody-Drug Conjugates for Cancer Treatment

R. Chari, V. Goldmacher, J. Lambert, 2002 .

Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage.

R. Lutz, Rajeeva Singh, Hongsheng Xie, 2011, Bioconjugate chemistry.

Antibody-Drug Conjugates for Cancer Treatment.

A. Berkenblit, J. Lambert, 2018, Annual review of medicine.

A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

R. Houot, B. Coiffier, H. Tilly, 2013, Clinical Cancer Research.

Drug‐conjugated antibodies for the treatment of cancer

J. Lambert, 2013, British journal of clinical pharmacology.

Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.

L. Gordon, A. Younes, L. Kwak, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ADME of Antibody–Maytansinoid Conjugates

H. Erickson, J. Lambert, John M. Lambert, 2012, The AAPS Journal.

Purified immunotoxins that are reactive with human lymphoid cells. Monoclonal antibodies conjugated to the ribosome-inactivating proteins gelonin and the pokeweed antiviral proteins.

A. Yau-Young, P. Senter, V. Goldmacher, 1985, The Journal of biological chemistry.

acute myeloid leukemia cells Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of

M. Belvin, J. Ritz, J. Griffin, 2011 .

trial of daily bolus infusion Serotherapy of B-cell neoplasms with anti-B 4-blocked ricin : a phase

N. Spector, K. Dear, J. Lambert, 2003 .

Anti-CD6-blocked ricin: an anti-pan T-cell immunotoxin.

S. Shah, V. Goldmacher, J. Lambert, 1994, International journal of immunopharmacology.

Evaluation of the systemic toxicity and pharmacokinetics of the immunoconjugate anti-B4-blocked ricin in non-human primates. Delivered by multiple bolus injections and by continuous infusion.

J. Taylor, S. Shah, V. Goldmacher, 1993, International journal of immunopharmacology.

Correlation between in vivo toxicity and preclinical in vitro parameters for the immunotoxin anti-B4-blocked ricin.

L. Nadler, V. Goldmacher, J. Lambert, 1992, Cancer research.

The specific cytotoxicity of immunoconjugates containing blocked ricin is dependent on the residual binding capacity of blocked ricin: evidence that the membrane binding and A-chain translocation activities of ricin cannot be separated.

V. Goldmacher, J. Lambert, W. Blattler, 1992, Biochemical and biophysical research communications.

Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion

J. Ritz, A. Freedman, N. Spector, 1992 .

Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells.

M. Belvin, J. Ritz, J. Griffin, 1991, Blood.

Synthesis and biological evaluation of antibody conjugates of phosphate prodrugs of cytotoxic DNA alkylators for the targeted treatment of cancer.

R. Chari, V. Goldmacher, H. Erickson, 2012, Journal of medicinal chemistry.

Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates.

Rajeeva Singh, A. Lazar, R. Chari, 2011, Journal of medicinal chemistry.

Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study.

A. Tolcher, C. Takimoto, L. Smith, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antibody–Drug Conjugates for Targeted Cancer Therapy

T. Chittenden, R. Chari, V. Goldmacher, 2012 .

Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study

A. Tolcher, C. Takimoto, L. Smith, 2008, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics and Biodistribution of the Antitumor Immunoconjugate, Cantuzumab Mertansine (huC242-DM1), and Its Two Components in Mice

Hongsheng Xie, J. Lambert, W. Blättler, 2004, Journal of Pharmacology and Experimental Therapeutics.

HuC242-DM4, an antibody-maytansinoid conjugate with superior preclinical activity in human CanAg-positive tumor xenograft models in SCID mice

R. Lutz, Hongsheng Xie, R. Chari, 2005 .

The pharmacokinetics and toxicity of murine monoclonal antibodies and of gelonin conjugates of these antibodies.

R. Sobel, B. Benacerraf, V. Goldmacher, 1987, International journal of immunopharmacology.

Antibody–Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review

J. Lambert, Charles Q. Morris, 2017, Advances in Therapy.

Typical Antibody–Drug Conjugates

J. Lambert, 2016 .

Antibody-drug conjugates: targeted delivery and future prospects.

J. Lambert, 2016, Therapeutic delivery.

Conjugation of blocked ricin to an anti-CD19 monoclonal antibody increases antibody-induced cell calcium mobilization and CD19 internalization.

D. Roy, V. Goldmacher, J. Lambert, 1997, Blood.

Antibody-Drug Conjugates (ADCs): Magic Bullets at Last!

J. Lambert, 2015, Molecular pharmaceutics.

Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates.

J. Pinkas, T. Keating, R. Chari, 2016, Bioconjugate chemistry.

Fourth World Antibody-Drug Conjugate Summit

A. Beck, Michael M C Sun, J. Lambert, 2012, mAbs.

Use of radiolabeled monoclonal anti-B1 antibody for B lymphocyte imaging in rhesus monkeys.

H. Atkins, N. Letvin, L. Nadler, 1987, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

A novel anti-CD 37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies

T. Chittenden, J. Pinkas, R. Lutz, 2013 .

A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies.

T. Chittenden, J. Pinkas, R. Lutz, 2013, Blood.

Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer.

R. Chari, J. Lambert, 2014, Journal of medicinal chemistry.

A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity

E. K. Maloney, J. Pinkas, Rajeeva Singh, 2016, Molecular Cancer Therapeutics.

Patents and literature

B. L. Scallet, E. Turkov, D. Jackson, 1987 .

Resting human peripheral blood lymphocytes can be activated to cytolytic function by antibodies to CD3 in the absence of exogenous interleukin-2.

J. Lambert, C. Scott, W. Blattler, 1988, Cellular immunology.

The influence of beta-arrestin2 on cannabinoid CB1 receptor coupling to G-proteins and subcellular localization and relative levels of beta-arrestin1 and 2 in mouse brain

C. Breivogel, R. Razdan, J. Lambert, 2013, Journal of receptor and signal transduction research.

Ricin A Chain Can Be Chemically Cross-linked to the Mammalian Ribosomal Proteins L9 and L10e (*)

C. Vater, J. Leszyk, V. Goldmacher, 1995, The Journal of Biological Chemistry.

Requirements for the construction of antibody heterodimers for the direction of lysis of tumors by human T cells.

C. Morimoto, J. Lambert, S. Schlossman, 1988, The Journal of clinical investigation.

Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma.

J. Gribben, J. Taylor, A. Freedman, 1993, Blood.

Blocked ricin-conjugated T cell immunotoxins: Effect of anti-CD6-blocked ricin on normal T cell function

J. Lambert, R. Rasmussen, A. Collinson, 2005, Cancer Immunology, Immunotherapy.

Elimination of B-lineage leukemia and lymphoma cells from bone marrow grafts using anti-B4-blocked-ricin immunotoxin

C. Perreault, J. Ritz, Denis Roy, 2005, Journal of Clinical Immunology.

An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use.

L. Nadler, V. Goldmacher, J. Lambert, 1991, Cancer research.

Immunotoxins containing single-chain ribosome-inactivating proteins.

V. Goldmacher, J. Lambert, G. McIntyre, 1988, Cancer treatment and research.

Cantuzumab M ertansine, a M aytansinoid I mmunoconjugate Directed t o t he C anAg A ntigen: A P hase I , P harmacokinetic, and B iologic C orrelative S tudy

A. Tolcher, C. Takimoto, L. Smith, 2003 .

Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients (pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL).

R. Houot, C. Copie-Bergman, B. Coiffier, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Multi-Dose Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous (IV) Infusion Every 3 Weeks to Patients with Relapsed/ Refractory B-Cell Non-Hodgkin's Lymphoma (NHL).

L. Gordon, A. Younes, L. Kwak, 2009 .

Sensitivity to Δ9-tetrahydrocannabinol is selectively enhanced in beta-arrestin2−/− mice

C. Breivogel, R. Razdan, J. Lambert, 2008, Behavioural pharmacology.

New heterobifunctional protein cross linking reagent that forms an acid labile link

P. Senter, J. Lambert, W. Blattler, 1985 .

Photoactivation of toxin conjugates.

P. Senter, V. Goldmacher, J. Lambert, 1992, Bioconjugate chemistry.

cell pool nonhuman primates: I. Effects of anti-T11 antibodies on the circulating T In vivo administration of lymphocyte-specific monoclonal antibodies in

J. Ritz, N. Letvin, J. Lambert, 2011 .

In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates: I. Effects of anti-T11 antibodies on the circulating T cell pool.

E. Reinherz, J. Ritz, N. Letvin, 1985, Blood.

Galactose-induced dimerization of blocked ricin at acidic pH: evidence for a third galactose-binding site in ricin B-chain.

J. Lambert, Y. P. Venkatesh, 1997, Glycobiology.

Levels of ribosomal protein S1 and elongation factor G in the growth cycle of Escherichia coli

R. Traut, J. Lambert, J. G. Howe, 1983, Journal of bacteriology.

Conjugation of Blocked Ricin to an Anti-CD19 Monoclonal Antibody Increases Antibody-Induced Cell Calcium Mobilization and CD19 Internalization

D. Roy, V. Goldmacher, J. Lambert, 1997 .

Effects of anti-CD33 blocked ricin immunotoxin on the capacity of CD34+ human marrow cells to establish in vitro hematopoiesis in long-term marrow cultures.

M. Cutting, J. Griffin, V. L. La Russa, 1992, Experimental hematology.

Functional domains involved in aromatic amino acid biosynthesis.

J. Coggins, D. Mousdale, D. Smith, 1985, Biochemical Society transactions.

Radioiodination of microgram quantities of ribosomal proteins from polyacrylamide gels.

R. Traut, J. Lambert, T. Fanning, 1980, Analytical biochemistry.

Cross-linking of ribosomes using 2-iminothiolane (methyl 4-mercaptobutyrimidate) and identification of cross-linked proteins by diagonal polyacrylamide/sodium dodecyl sulfate gel electrophoresis.

R. Traut, J. Lambert, J. Kenny, 1979, Methods in enzymology.

Realizing the full potential of immunotoxins.

V. Goldmacher, J. Lambert, W. Blättler, 1989, Cancer cells.

In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. V. Evidence that humoral immune response to monoclonal antibodies and immunotoxin conjugates abrogates their cytotoxic activity.

N. Letvin, K. Reimann, J. Lambert, 1989, Transplantation.

In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. Delivery of ribosome-inactivating proteins to spleen and lymph node T cells.

J. Ritz, N. Letvin, K. Reimann, 1986, The Journal of clinical investigation.

The arom multifunctional enzyme from Neurospora crassa.

J. Coggins, S. Chaudhuri, D. Smith, 1987, Methods in enzymology.

Purification and characterization of 3-dehydroquinase from Escherichia coli.

J. Coggins, S. Chaudhuri, J. Lambert, 1986, The Biochemical journal.

A New Triglycyl Peptide Linker for Antibody–Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells

Rajeeva Singh, Y. Setiady, Rui Wu, 2016, Molecular Cancer Therapeutics.

Ribosomal protein L7/L12 cross-links to proteins in separate regions of the 50 S ribosomal subunit of Escherichia coli.

R. Traut, J. Lambert, J. Kenny, 1983, The Journal of biological chemistry.

Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models

R. Lutz, J. Lambert, C. N. Carrigan, 2014, mAbs.

SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies

R. Lutz, A. Bousseau, V. Blanc, 2011, Clinical Cancer Research.

SAR 3419 : An Anti-CD 19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies

R. Lutz, A. Bousseau, V. Blanc, 2011 .

Elimination of neuroblastoma and small-cell lung cancer cells with an anti-neural cell adhesion molecule immunotoxin.

C Perreault, C. Perreault, Denis Roy, 1996, Journal of the National Cancer Institute.

The antileukemic efficacy of an immunotoxin composed of a monoclonal anti-Thy-1 antibody disulfide linked to the ribosome-inactivating protein gelonin

R. Chari, V. Goldmacher, J. Lambert, 2004, Cancer Immunology, Immunotherapy.

Identification of three oligosaccharide binding sites in ricin.

J. Lambert, R. Steeves, M. Denton, 1999, Biochemistry.

Antibody-complement-mediated cytotoxicity is enhanced by ribosome-inactivating proteins.

P. Senter, V. Goldmacher, J. Lambert, 1985, Journal of immunology.

Folding domains and intramolecular ionic interactions of lysine residues in glyceraldehyde 3-phosphate dehydrogenase.

R. Perham, J. Lambert, 1977, The Biochemical journal.

Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism

John M. Lambert, John Sondek, David P. Siderovski, 2002, Nature Cell Biology.

Cytotoxicity of gelonin and its conjugates with antibodies is determined by the extent of their endocytosis

S. Watkins, S. Cook, V. Goldmacher, 1989, Journal of cellular physiology.

Somatic cell mutants resistant to ricin, diphtheria toxin, and to immunotoxins.

V. Goldmacher, J. Lambert, J. Anderson, 1987, The Journal of biological chemistry.

In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. In vivo stability of disulfide-linked immunotoxin conjugates.

J. Ritz, N. Letvin, V. Goldmacher, 1986, The Journal of clinical investigation.

Addition of sulfhydryl groups to Escherichia coli ribosomes by protein modification with 2-iminothiolane (methyl 4-mercaptobutyrimidate).

R. Traut, J. Lambert, J M Lambert, 1978, Biochemistry.

Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia

A. Vekhoff, D. DeAngelo, C. Dumontet, 2012, Investigational New Drugs.

In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. IV. Cytotoxic effect of an anti-T11-gelonin immunotoxin.

N. Letvin, K. Reimann, S. Cook, 1988, The Journal of clinical investigation.

NOVEL PHOTOCLEAVABLE PROTEIN CROSSLINKING REAGENTS AND THEIR USE IN THE PREPARATION OF ANTIBODY‐TOXIN CONJUGATES

P. Senter, J. Lambert, W. Blattler, 1985 .

Use of retrovirus expression of interfering RNA to determine the contribution of activated K-Ras and ras effector expression to human tumor cell growth.

C. Der, A. Baines, J. M. Shields, 2006, Methods in enzymology.

Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion.

J. Ritz, A. Freedman, N. Spector, 1992, Blood.

Modification of the binding site(s) of lectins by an affinity column carrying an activated galactose-terminated ligand.

S. Moroney, V. Goldmacher, J. Lambert, 1987, Biochemistry.

Targeting CD56 (NCAM)-Expressing Neoplasms with Lorvotuzumab Mertansine

V. Goldmacher, J. Lambert, K. Whiteman, 2013 .

Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation.

R. Lutz, V. Blanc, H. Erickson, 2015, Molecular pharmaceutics.

Role of MLK3-mediated Activation of p70 S6 Kinase in Rac1 Transformation*

C. Der, L. Graves, S. Campbell, 2002, The Journal of Biological Chemistry.

Targeting CD19 with SAR3419, an anti-CD19-Maytansinoid Conjugate for the Treatment of B Cell Malignancies

A. Bousseau, V. Blanc, J. Lambert, 2013 .

Cure of multidrug-resistant human B-cell lymphoma xenografts by combinations of anti-B4-blocked ricin and chemotherapeutic drugs.

R. O'Connor, J. Lambert, C. Liu, 1996, Blood.

Identification of proteins at the subunit interface of the Escherichia coli ribosome by cross-linking with dimethyl 3,3'-dithiobis(propionimidate).

R. Traut, C. Norman, J. Lambert, 1981, Biochemistry.

The subunit interface of the Escherichia coli ribosome. Crosslinking of 30 S protein S9 to proteins of the 50 S subunit.

R. Traut, J. Lambert, T. Fanning, 1979, Journal of molecular biology.

The INNs and outs of antibody nonproprietary names

Andreas Plückthun, James S. Huston, John M. Lambert, 2015, mAbs.

Intramolecular ionic interactions of lysine residues and a possible folding domain in fructose diphosphate aldolase.

J. Coggins, R. Perham, J. Lambert, 1977, The Biochemical journal.

The subunit interface of the Escherichia coli ribosome. Identification of proteins at the interface between the 30 S and 50 S subunits by crosslinking with 2-iminothiolane.

R. Traut, J. Lambert, 1981, Journal of molecular biology.

Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms.

J. Taylor, N. Spector, V. Goldmacher, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Topoisomerase II cleavable complex formation within DNA loop domains.

J. Lambert, D. Fernandes, 2000, Biochemical pharmacology.

An Open Label, Dose Escalation Study of AVE9633 Administered as a Single Agent by Intravenous (IV) Infusion Weekly for 2 Weeks in 4-Week Cycle to Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia (AML).

J. Miguel, C. Dumontet, X. Thomas, 2007 .

A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing.

A R Rees, J T Pedersen, A. Henry, 1996, Protein engineering.

Construction bifonctionnelle d'anticorps et procédé de destruction sélective de populations de cellules

J. Lambert, S. Schlossman, C. Scott, 1988 .

Disulfide cross-linking of Escherichia coli ribosomal proteins with 2-iminothiolane (methyl 4-mercaptobutyrimidate): evidence that the cross-linked protein pairs are formed in the intact ribosomal subunit.

R. Traut, J. Lambert, J M Lambert, 1978, Biochemistry.

Anti‐B4‐blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma

D. Esseltine, L. Nadler, P. Fidias, 1998, British journal of haematology.

IMGN853, a Folate Receptor-α (FRα)–Targeting Antibody–Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors

T. Chittenden, J. Pinkas, R. Lutz, 2015, Molecular Cancer Therapeutics.

Structural characterization of the maytansinoid–monoclonal antibody immunoconjugate, huN901–DM1, by mass spectrometry

John M Lambert, Wei Zhang, J. Lambert, 2005, Protein science : a publication of the Protein Society.

Formation of N-substituted 2-iminothiolanes when amino groups in proteins and peptides are modified by 2-iminothiolane.

J. Lambert, W. Blättler, L. Kats, 1996, Analytical biochemistry.

Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin.

D. Esseltine, J. Ritz, T. Lynch, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A reversed-phase high-performance liquid chromatography method for analysis of monoclonal antibody-maytansinoid immunoconjugates.

Wei Zhang, M. S. Fleming, J. Lambert, 2005, Analytical biochemistry.

ADME of Antibody–Maytansinoid Conjugates

H. Erickson, J. Lambert, 2012, The AAPS Journal.

Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry.

A. Lazar, Wei Zhang, J. Lambert, 2005, Rapid communications in mass spectrometry : RCM.

Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma.

V. Goldmacher, J. Lambert, R. Rasmussen, 1994, Blood.

Antibody‐Drug Conjugates: New Frontier in Cancer Therapeutics

Rajeeva Singh, R. Chari, J. Lambert, 2014 .

Cytotoxic Drug Conjugate − Trastuzumab-DM 1 , an Antibody Targeting HER 2-Positive Breast Cancer with Updated

M. Sliwkowski, H. Koeppen, R. Lutz, 2008 .

Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma [see comments]

Rasmus A. Rasmussen, V. Goldmacher, J. Lambert, 1994 .

Evaluation of Targets for Maytansinoid ADC Therapy Using a Novel Radiochemical Assay

Y. Setiady, R. Chari, J. Lambert, 2015, Pharmaceutical Research.

Human T cells can be directed to lyse tumor targets through the alternative activation/T11-E rosette receptor pathway.

C. Morimoto, J. Lambert, S. Schlossman, 1988, Journal of immunology.

Structural Characterization of a Recombinant Monoclonal Antibody by Electrospray Time-of-Flight Mass Spectrometry

John M. Lambert, Wei Zhang, J. Lambert, 2005, Pharmaceutical Research.

Phase I Study of AVE9633, an AntiCD33-Maytansinoid Immunoconjugate, Administered as an Intravenous Infusion in Patients with Refractory/Relapsed CD33-Positive Acute Myeloid Leukemia (AML).

S. Verstovsek, F. Ravandi, D. DeAngelo, 2006 .

Activation of human cytolytic cells through CD2/T11. Comparison of the requirements for the induction and direction of lysis of tumor targets by T cells and NK cells.

J. Ritz, C. Morimoto, J. Lambert, 1989, Journal of immunology.

Antibody–drug conjugates come of age in oncology

J. Reichert, C. Dumontet, A. Beck, 2023, Nature Reviews Drug Discovery.

Mutational and structural analysis of the lectin activity in binding domain 2 of ricin B chain.

R. Kamath, J. Pedersen, S. Lehar, 1994, Protein engineering.

A comparison of the glyceraldehyde 3‐phosphate dehydrogenase from ox muscle and liver

R. Perham, J. Lambert, 1974, FEBS letters.

Expression of the common acute lymphoblastic leukemia antigen (CALLA) on the surface of individual cells of human lymphoblastoid lines.

J. Ritz, V. Goldmacher, J. Lambert, 1986, Journal of immunology.

[42] The arom multifunctional enzyme from neurospora crassa

J. Coggins, S. Chaudhuri, G. Nimmo, 1987 .

Epstein Barr virus binding induces internalization of the C3d receptor: a novel immunotoxin delivery system.

T. Tedder, V. Goldmacher, J. Lambert, 1986, Journal of immunology.